UNSPSC 51323106: Fosmenic acid

This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VD27I23138, chemically known as [cyclohex-3-en-1-yl(hydroxy)methyl]-hydroxy-oxo-phosphonium, which bears US NIH Compound Identifier 6338284, but generally known as fosmenic acid. European Medicines Agency schedules Fosmenic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07801MIG. Fosmenic acid generally arises in the molecular formula C7H13O3P.

The term FOSMENIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) As of Q4 2014, FOSMENIC ACID remains the US FDA Preferred Term for this commodity. Fosmenic acid bears US NLM identifiers UMLS ID C1880847 and NCI Concept Code C65763. SMILES: P(=O)(O)C(O)C1CCC=CC1.

UNSPSC 51323106 Fosmenic acid is a Commodity code that in practice captures state and local procurement of emergency pharmaceuticals and medications for use by first responders and health systems, rather than the specific chemical compound its nominal name suggests. State and local governments soliciting under this code include municipal fire and rescue departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. Recent solicitations show demand for sealed-bid supply of advanced life support medications (epinephrine, labetalol, adenosine, diltiazem), generic multi-source pharmaceuticals distributed through established wholesaler networks, and direct-to-manufacturer prescription fulfillment programs. The City of Tampa Fire Rescue's April 2026 IFB for Advanced Life Support Medications (Bid No. 26-P-00188) sought 370 units of labetalol, 1,810 units of epinephrine, 330 units of adenosine, and 1,020 units of diltiazem with nine-month minimum shelf life and ten-day delivery, estimated at $40,000 and open to Small Local Business Enterprise participation at a 5 percent bid discount. Work under this code demands compliance with FDA standards, OSHA Hazard Communication Standards for Safety Data Sheets, current Good Manufacturing Practices, and Drug Supply Chain Security Act requirements; vendors also must warrant products free from defects for 365 days and manage expiration logistics.

Recent activity spans Florida, Texas, and Minnesota through a mix of municipal purchasing (City of Tampa), state health agencies (Texas HHS Commission), and multi-state cooperative purchasing (MMCAP administered by Minnesota Department of Administration). The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through AmerisourceBergen, Cardinal Health, and Morris & Dickson with pricing evaluation weighted 75 percent on price competitiveness and contracts effective July 1, 2026. The Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, signaling state interest in supply-chain restructuring. Municipal and state opportunities under this code typically demand firm, all-inclusive pricing with freight and taxes absorbed by the vendor, insurance coverage minimums ($5 million general liability typical), and one-year contract terms with renewal options. Set-asides and small-business preferences vary by jurisdiction—Tampa applies SLBE sheltering; MMCAP does not specify disadvantaged-enterprise restrictions in available documentation.